Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Universal Technical Institute (UTI)

Universal Technical Institute reported revenue growth of 7.2% for fiscal Q3 2026. On the same day, the Company lowered its baseline adjusted EBITDA outlook by roughly $20 million -- and UTI shares sold off sharply.

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Universal Technical Institute (NYSE: UTI) shareholders watched the stock drop after the Company paired 7.2% revenue growth with a fiscal 2026 baseline adjusted EBITDA outlook of above $135 million, down from more than $155 million. Investors who lost money on UTI shares are encouraged to submit their loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

The two numbers landed together. Revenue for the quarter: $218.9 million, up 7.2% year over year. Baseline adjusted EBITDA guidance for the full year: cut by approximately $20 million, or roughly 13% off the prior figure. Enrollment metrics improved in the same period.

Management attributed approximately 70% of the EBITDA reduction to weaker-than-expected fourth-quarter starts in the high-school auto and diesel channel. The remainder was attributed to a faster mix shift toward shorter-duration, lower-margin programs. Levi & Korsinsky is investigating potential securities law violations on behalf of UTI investors.

Shareholders who purchased UTI stock and suffered a loss are encouraged to click here to learn more about the investigation, or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the UTI Investigation

Q: Who is eligible to participate in the UTI investigation? A: Investors who purchased UTI stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did UTI stock drop? A: Shares declined sharply following the fiscal Q3 2026 earnings release, from a closing price of $42.37 on August 5, 2026, share price declined to close at only $27.87, a fall of $14.50 per share, or nearly 35%. Investors who purchased UTI shares and suffered losses may be eligible to seek recovery.

Q: Who is conducting the UTI investigation? A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased UTI securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: What do UTI investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my UTI shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought UTI and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.